Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Tables)

v3.20.2
Net Loss Per Share (Tables)
9 Months Ended
Sep. 30, 2020
Net Loss Per Share  
Schedule of reconciliation of net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended

 

For the Nine Months Ended

 

 

September 30,

 

September 30,

 

    

2020

    

2019

    

2020

    

2019

Net loss

 

$

(8,916,433)

 

$

(6,330,913)

 

$

(19,826,671)

 

$

(17,094,899)

Net loss - Non-controlling interest

 

 

(64,824)

 

 

(136,315)

 

 

(228,526)

 

 

(413,955)

Net loss attributable to Heat Biologics, Inc.

 

$

(8,851,609)

 

$

(6,194,598)

 

$

(19,598,145)

 

$

(16,680,944)

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average number of common shares used in net loss per share attributable to common stockholders —basic and diluted

 

 

143,728,870

 

 

33,650,829

 

 

96,481,271

 

 

33,255,535

Net loss per share attributable to Heat Biologics, Inc —basic and diluted

 

$

(0.06)

 

$

(0.18)

 

$

(0.20)

 

$

(0.50)

 

Schedule of potentially dilutive securities

 

 

 

 

 

 

    

2020

    

2019

Outstanding stock options

 

9,156,865

 

3,163,354

Restricted stock subject to forfeiture and restricted stock units

 

2,025,215

 

838,429

Outstanding common stock warrants

 

5,739,064

 

9,030,730